SIG 1311

Drug Profile

SIG 1311

Alternative Names: SIG-1311

Latest Information Update: 11 Aug 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Signum Biosciences
  • Developer Signum Dermalogix
  • Class Small molecules; Terpenes
  • Mechanism of Action G protein-coupled receptor modulators; Signal transduction pathway modulators; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis

Most Recent Events

  • 11 Aug 2016 Discontinued for Atopic dermatitis in USA (Topical)
  • 24 Sep 2010 Signum Biosciences receives two SBIR grants from the NIAMS for the development of GPCR modulating agents in Skin disorders.
  • 13 Jul 2010 Early research in Atopic dermatitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top